PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?

Background: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear. Aim: We conducted a literature analysis with the aim to evaluate the efficacy and safety profile of a combination with RT and PAR...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amelia Barcellini, Pierre Loap, Kazutoshi Murata, Riccardo Villa, Youlia Kirova, Noriyuki Okonogi, Ester Orlandi
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	BRCA PARP-I Poly-ADP ribose polymerase radiotherapy toxicity synthetic lethality Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c236196a40cd44788e22d26676f07db4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c236196a40cd44788e22d26676f07db4
record_format	dspace
spelling	oai:doaj.org-article:c236196a40cd44788e22d26676f07db42021-11-11T15:29:42ZPARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?10.3390/cancers132153802072-6694https://doaj.org/article/c236196a40cd44788e22d26676f07db42021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5380https://doaj.org/toc/2072-6694Background: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear. Aim: We conducted a literature analysis with the aim to evaluate the efficacy and safety profile of a combination with RT and PARP-I. Method: The key issues for the current review were expressed in two questions according to the Population, Intervention, Control, Outcome (PICO) criteria: 1. What is the outcome and 2. What is the toxicity in patients treated with a combination of PARP-I and RT for a newly diagnosed or recurrent tumors? Results: A total of 12 clinical studies met the inclusion criteria including seven single-arm dose-escalation phase I studies, two phase II (two- and three-arms controlled trials) trials, one parallel-arm phase I study, and two phase I/II studies published between 2015 and 2021. RT was performed with photon beams and several schedules according to the clinical situation. The acute toxicity ≥ grade 3 ranged between 25% and >96%, which was divided into hematological or non-hematological adverse events. Conclusions: despite the heterogeneity of the evaluated patient populations and tumor types, and the limited number of the studies, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear.Amelia BarcelliniPierre LoapKazutoshi MurataRiccardo VillaYoulia KirovaNoriyuki OkonogiEster OrlandiMDPI AGarticleBRCAPARP-IPoly-ADP ribose polymeraseradiotherapytoxicitysynthetic lethalityNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5380, p 5380 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	BRCA PARP-I Poly-ADP ribose polymerase radiotherapy toxicity synthetic lethality Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	BRCA PARP-I Poly-ADP ribose polymerase radiotherapy toxicity synthetic lethality Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Amelia Barcellini Pierre Loap Kazutoshi Murata Riccardo Villa Youlia Kirova Noriyuki Okonogi Ester Orlandi PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
description	Background: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear. Aim: We conducted a literature analysis with the aim to evaluate the efficacy and safety profile of a combination with RT and PARP-I. Method: The key issues for the current review were expressed in two questions according to the Population, Intervention, Control, Outcome (PICO) criteria: 1. What is the outcome and 2. What is the toxicity in patients treated with a combination of PARP-I and RT for a newly diagnosed or recurrent tumors? Results: A total of 12 clinical studies met the inclusion criteria including seven single-arm dose-escalation phase I studies, two phase II (two- and three-arms controlled trials) trials, one parallel-arm phase I study, and two phase I/II studies published between 2015 and 2021. RT was performed with photon beams and several schedules according to the clinical situation. The acute toxicity ≥ grade 3 ranged between 25% and >96%, which was divided into hematological or non-hematological adverse events. Conclusions: despite the heterogeneity of the evaluated patient populations and tumor types, and the limited number of the studies, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear.
format	article
author	Amelia Barcellini Pierre Loap Kazutoshi Murata Riccardo Villa Youlia Kirova Noriyuki Okonogi Ester Orlandi
author_facet	Amelia Barcellini Pierre Loap Kazutoshi Murata Riccardo Villa Youlia Kirova Noriyuki Okonogi Ester Orlandi
author_sort	Amelia Barcellini
title	PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
title_short	PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
title_full	PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
title_fullStr	PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
title_full_unstemmed	PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
title_sort	parp inhibitors in combination with radiotherapy: to do or not to do?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/c236196a40cd44788e22d26676f07db4
work_keys_str_mv	AT ameliabarcellini parpinhibitorsincombinationwithradiotherapytodoornottodo AT pierreloap parpinhibitorsincombinationwithradiotherapytodoornottodo AT kazutoshimurata parpinhibitorsincombinationwithradiotherapytodoornottodo AT riccardovilla parpinhibitorsincombinationwithradiotherapytodoornottodo AT youliakirova parpinhibitorsincombinationwithradiotherapytodoornottodo AT noriyukiokonogi parpinhibitorsincombinationwithradiotherapytodoornottodo AT esterorlandi parpinhibitorsincombinationwithradiotherapytodoornottodo
_version_	1718435267518398464

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?

Ejemplares similares